Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.
Capmatinib is an oral, ATP-competitive, and a highly potent, type 1b MET inhibitor. Here, we report phase I dose-escalation results for capmatinib in advanced MET-positive solid tumor patients and dose-expansion in advanced non-lung tumors. Capmatinib was well tolerated with a manageable safety profile across all explored doses. Dose-limiting toxicities (DLTs) occurred at 200 mg twice daily (bid), 250 mg bid, and 450 mg bid capsules; however, no DLTs were reported at 600 mg bid (capsules). Capmatinib tablets at 400 mg bid had comparable tolerability and exposure to that of 600 mg bid capsules. The maximum-tolerated dose was not reached; recommended phase 2 dose was 400 mg bid tablets/600 mg bid capsules; at this dose, Ctrough > EC90 (90% inhibition of c-MET phosphorylation in animal models) is expected to be achieved and maintained. Among the dose-expansion patients (N=38), best overall response across all cohorts was stable disease (gastric cancer 22%, hepatocellular carcinoma 46%, other indications 28%); 2 other indication patients with gene copy number (GCN) ≥6 achieved substantial tumor reduction. Near-complete immunohistochemically determined phospho-MET inhibition (H-score=2) was demonstrated following capmatinib 450 mg bid capsule in paired biopsies obtained from 1 advanced CRC patient. Incidence of high-level MET GCN (GCN ≥6) and MET overexpressing (immunohistochemistry 3+) tumors in the expansion cohorts was 8% and 13%, respectively; no MET mutations were observed. Thus, the RP2D of capmatinib was 600 mg bid capsule/400 mg bid tablet. Capmatinib was well tolerated and showed antitumor activity and acceptable safety profile at the R2PD.